This HTML5 document contains 123 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
n11	http://dx.doi.org/10.1016/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n8	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q28185278

rdf:type

wikibase:Item

schema:description

article scientific 2003年论文 article científic mokslinis straipsnis naučni članak articol științific научни чланак 2003 թուականի Մայիսին հրատարակուած գիտական յօդուած научная статья мақолаи илмӣ სამეცნიერო სტატია наукова стаття, опублікована в травні 2003 vedecký článok (publikovaný 2003/05/01) vědecký článek publikovaný v roce 2003 artigo científico 2003年論文 2003年论文 บทความทางวิทยาศาสตร์ scienca artikolo επιστημονικό άρθρο tudományos cikk artykuł naukowy teaduslik artikkel artigo científico artículu científicu espublizáu en 2003 научни чланак articolo scientifico 2003年論文 vetenskaplig artikel tieteellinen artikkeli ২০০৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2003年论文 scientific article (publication date: May 2003) artikull shkencor مقالة علمية (نشرت في مايو 2003) 2003년 논문 מאמר מדעי 2003年論文 artigo científico 2003年论文 wetenschappelijk artikel (gepubliceerd op 2003/05/01) artículo científico publicado en 2003 bilimsel makale vitenskapelig artikkel bài báo khoa học 2003年論文 научна статия 2003年论文 2003年论文 мақолаи илмӣ wissenschaftlicher Artikel article scientifique 2003 թվականի մայիսին հրատարակված գիտական հոդված 2003 nî lūn-bûn 2003年論文 artikulong pang-agham videnskabelig artikel 2003年の論文 vitskapeleg artikkel

p:P577

wds:Q28185278-FCE773AC-2F5E-4E84-BCDC-F9CDB94E6229

wdt:P577

2003-05-01T00:00:00Z

p:P407

wds:Q28185278-08C289CB-F060-4579-8CCE-AAE9509D531F

wdt:P407

wd:Q1860

p:P2093

wds:Q28185278-3C521CF3-82FD-4DAC-9841-924C869237B9 wds:Q28185278-42E9AD45-7C5E-4534-9374-2493DEB5ACB2 wds:Q28185278-3BCFDBA1-3773-4821-A187-3F98A45F70CD wds:Q28185278-28CAA289-197C-4A5F-8CBA-07DFCA222E9A wds:Q28185278-B9A06118-6F9C-45EB-B10A-36844B474FE3 wds:Q28185278-8924A284-0C75-4B64-9544-1C9E8AF799BA wds:Q28185278-D1779AF3-5316-40C1-974E-F6D940BBA219 wds:Q28185278-2641E003-444A-460B-9130-22F31114987C wds:Q28185278-26B5FEDA-14AF-4452-8A0A-FD4FF31B0C23

wdt:P2093

S Lindborg D Perkins T J Miller J Addington M Tohen S W Woods R Hoffman K A Hawkins A Breier

rdfs:label

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design

skos:prefLabel

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design

schema:name

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design

p:P50

wds:Q28185278-B3BC0EBD-A6CB-4293-AE58-E6751A12D40F wds:Q28185278-3746A9DB-7784-4721-9F76-785BF26CF47C

wdt:P50

wd:Q7792302 wd:Q24067148

p:P1476

wds:Q28185278-215F1972-1373-4AC0-8F03-6218DC7F8C6A

wdt:P1476

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design

p:P304

wds:Q28185278-BE0749C3-A086-4E3F-92A0-CE012770D7BB

wdt:P304

7-18

p:P31

wds:Q28185278-A9900B63-6FB0-427A-BB4E-B434F3B103DD wds:Q28185278-33D404D1-43F3-4FED-BB3F-B9C22CD1C955

wdt:P31

wd:Q13442814 wd:Q30612

p:P921

wds:Q28185278-F858F984-A009-4984-A525-A9474626F410 wds:Q28185278-AF29BDD5-FB39-4431-BA4B-2D7E4BA952B0 wds:Q28185278-8B65147B-E0BD-4CF6-A670-EE89D0946CDB wds:Q28185278-470BDE0F-8E99-42AB-9AE9-564EC244B09A

wdt:P921

wd:Q108483352 wd:Q170082 wd:Q181600 wd:Q269829

p:P698

wds:Q28185278-DCB790E6-163F-428C-BF6C-63F22BF3CAD5

wdtn:P698

n8:12648731

wdt:P698

12648731

p:P1433

wds:Q28185278-DF841A3B-B8B1-4F43-803F-5DC2999374E8

wdt:P1433

wd:Q7431607

p:P433

wds:Q28185278-617861A2-BBBC-42B5-93F1-E1CAF2BF5115

p:P478

wds:Q28185278-A6E4CB27-47FD-49A8-9F61-7C712D2B4D99

wdt:P433

1

wdt:P478

61

p:P356

wds:Q28185278-F0861B9B-F018-4BAB-92B0-8CD0F00E27E9

wdtn:P356

n11:S0920-9964(02)00439-5

wdt:P356

10.1016/S0920-9964(02)00439-5